8AT Stock Overview
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aclaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.12 |
| 52 Week High | US$6.50 |
| 52 Week Low | US$0.59 |
| Beta | 0.23 |
| 1 Month Change | 7.69% |
| 3 Month Change | 5.66% |
| 1 Year Change | n/a |
| 3 Year Change | -95.01% |
| 5 Year Change | -80.13% |
| Change since IPO | -96.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8AT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.9% | -3.3% | -1.5% |
| 1Y | n/a | -30.8% | 0.9% |
Return vs Industry: Insufficient data to determine how 8AT performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 8AT performed against the German Market.
Price Volatility
| 8AT volatility | |
|---|---|
| 8AT Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8AT's share price has been volatile over the past 3 months.
Volatility Over Time: 8AT's weekly volatility has decreased from 22% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 89 | Neal Walker | www.aclaristx.com |
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. Fundamentals Summary
| 8AT fundamental statistics | |
|---|---|
| Market cap | €81.96m |
| Earnings (TTM) | -€83.13m |
| Revenue (TTM) | €29.36m |
2.8x
P/S Ratio-1.0x
P/E RatioIs 8AT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8AT income statement (TTM) | |
|---|---|
| Revenue | US$31.25m |
| Cost of Revenue | US$116.47m |
| Gross Profit | -US$85.22m |
| Other Expenses | US$3.27m |
| Earnings | -US$88.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | -272.70% |
| Net Profit Margin | -283.15% |
| Debt/Equity Ratio | 0% |
How did 8AT perform over the long term?
See historical performance and comparison